Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out drugs are emerging.

Obesity in an ageing population 'is biggest issue for the NHS' Wegovy, Ozempic, weight loss - and the future of obesity Junk food crackdown 'would slash ... in the UK linked to glucagon-like peptide ...

The Rock River Valley Blood Center will reward donors with free marijuana to inspire donations on Saturday. The “Bleed for Weed” blood drive will take place at the RRVBC’s Belvidere location, 1740 S ...

The best online providers offer strong support services to help you succeed in your GLP-1 weight loss journey.

The FDA is part of Health and Human Services, so Trump’s decision opens the path for Kennedy to shake up the agency, as he ...

There have been a slew of studies recently supporting the notion that the same mechanisms that help folks lose weight with ...

As optimism for GLP-1 receptor agonists for weight loss has grown, so too has their use in children. Currently, liraglutide ...

Estrogen is the primary culprit for weight gain in the hips, thighs and buttocks. The ovaries produce less estrogen during ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

A new study supports the notion that the same mechanisms that help folks lose weight with Ozempic and its kin also work to ...